Written by Austin Mao · Last updated: October 2026 · 8 cited studies.
Background: anxiety and the limits of first-line care
The National Institute of Mental Health estimates that about 31% of U.S. adults will experience an anxiety disorder at some point in their lives. Generalized anxiety disorder, social anxiety disorder, panic disorder, and specific phobias each have validated evidence-based treatments, typically a combination of selective serotonin reuptake inhibitors and exposure-based psychotherapy.
That care reaches many people. It does not reach everyone. Not everyone responds fully to first-line SSRIs, and there is additional attrition from side effects and a long latency to clinical effect. End-of-life anxiety in patients with terminal cancer has been the most extensively studied subtype in psilocybin trials so far.
That gap is the clinical question the trials below were designed to address.
Mechanism: how psilocybin acts on anxiety circuits
Psilocybin (via psilocin) is a partial agonist at serotonin 2A receptors, with high cortical-pyramidal density. Acute receptor activation drives transient disintegration of the default mode network and increases global functional connectivity. Kraehenmann et al. (2015) reported reduced right-amygdala BOLD response to negative stimuli in healthy volunteers under psilocybin, with the reduction tracking concurrent mood elevation.
The REBUS framework (Carhart-Harris & Friston, 2019) frames psychedelic action as a temporary relaxation of top-down predictive priors, allowing bottom-up signals to revise belief structures. Anxiety-disorder models built on rigid threat priors are a natural fit for this framework, though clinical trial confirmation in non-cancer anxiety populations is still developing. For deeper mechanism, see /research and /science/default-mode-network.
Preclinical work shows increased dendritic spine density in rodents (Ly et al., 2018; Shao et al., 2021: about 10% within 24 hours, persisting at one month in mice). Whether this is the substrate for behavior change in people is unproven, and no human plasticity window has been measured. See /science/neuroplasticity.
Clinical evidence: 8 cited studies
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Griffiths RR, Johnson MW, Carducci MA, et al.
Journal of Psychopharmacology · 2016
- Design
- Randomized, double-blind, crossover (high-dose vs. low-dose)
- N
- 51 (cancer-related anxiety and depression)
- Primary outcome
- HAM-A and BDI at 5 weeks and 6 months
- Reported effect
- About 80% of participants showed clinically significant reductions in anxiety and depression sustained at 6 months.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
Ross S, Bossis A, Guss J, et al.
Journal of Psychopharmacology · 2016
- Design
- Randomized, double-blind, crossover (psilocybin vs. niacin)
- N
- 29 (cancer-related anxiety and depression)
- Primary outcome
- HADS-A, HADS-D, BDI at 6.5 months
- Reported effect
- Roughly 60-80% sustained anti-anxiety and antidepressant response at 6.5 months. A within-subject follow-up of the cohort (Agin-Liebes 2020; uncontrolled, 15 of 16 survivors) found 60-80% still met response criteria at 4.5 years.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin GM, Aaronson ST, Alvarez O, et al.
New England Journal of Medicine · 2022
- Design
- Phase IIb, randomized, double-blind, dose-finding
- N
- 233 (treatment-resistant depression with anxiety symptoms)
- Primary outcome
- MADRS at week 3; HAM-A as secondary measure
- Reported effect
- 25 mg arm: 12-point MADRS reduction at week 3; secondary anxiety measures also moved in the same direction.
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
Davis AK, Barrett FS, May DG, et al.
JAMA Psychiatry · 2021
- Design
- Randomized, waitlist-controlled trial
- N
- 27 randomized, 24 analysed (MDD; anxiety as a secondary measure)
- Primary outcome
- GRID-HAMD; anxiety subscale at week 4
- Reported effect
- Large effect sizes on the depression primary outcome (Cohen's d > 2 at week 4); anxiety subscale moved in the same direction.
Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers
Kraehenmann R, Preller KH, Scheidegger M, et al.
Biological Psychiatry · 2015
- Design
- Within-subject, placebo-controlled fMRI
- N
- 25 (healthy volunteers)
- Primary outcome
- Amygdala BOLD response to threat stimuli; correlation with positive mood
- Reported effect
- Reduced right-amygdala reactivity to negative stimuli after psilocybin, with the magnitude correlating with mood elevation.
Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression
Roseman L, Nutt DJ, Carhart-Harris RL.
Frontiers in Pharmacology · 2018
- Design
- Open-label trial follow-up analysis
- N
- 20 (treatment-resistant depression)
- Primary outcome
- 5D-ASC dimensions (Oceanic Boundlessness, Dread of Ego Dissolution) vs. QIDS-SR change
- Reported effect
- Both Oceanic Boundlessness and Dread of Ego Dissolution predicted depression improvement; the 5-week correlation was specific to Oceanic Boundlessness. Mystical-experience mediation is documented in Griffiths 2016 and Ross 2016.
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
Carhart-Harris RL, Leech R, Hellyer PJ, et al.
Frontiers in Human Neuroscience · 2014
- Design
- Theoretical review with neuroimaging integration
- N
- Review (no single sample)
- Primary outcome
- Entropic-brain framework for psychedelic action
- Reported effect
- Proposes that psychedelic states correspond to elevated cortical entropy and reduced default-mode network integrity, with implications for rumination-linked disorders.
REBUS and the Anarchic Brain
Carhart-Harris RL, Friston KJ.
Pharmacological Reviews · 2019
- Design
- Theoretical model integrating predictive coding and 5-HT2A action
- N
- Theoretical model
- Primary outcome
- REBUS framework for psychedelic action
- Reported effect
- Frames psychedelic action as relaxed top-down priors enabling bottom-up signals to revise belief structures, relevant to anxiety models built on rigid threat priors.
Safety profile specific to anxiety
- Acute “challenging experience”: in Griffiths 2016, session monitors rated an episode of anxiety in 26% of high-dose sessions (15% of low-dose sessions) and any psychological discomfort in 32% (12% for low dose). The risk underlines why set, setting, and screening matter.
- Cardiovascular conditions: relative contraindication; psilocybin produces transient blood pressure and heart rate elevation. See /safety/screening.
- SSRIs and benzodiazepines: both blunt psilocybin effect. Your prescriber leads any taper; never stop or change a medication on your own. See /safety/medications.
- MAOIs: absolute contraindication.
- Bipolar I or II: absolute or relative contraindication due to mood-elevation risk.
- Personal or first-degree-relative history of psychosis: absolute contraindication.
Integration considerations for anxiety
Anxiety integration tends to favor somatic practice over cognitive-only protocols. The polyvagal framework (Porges) and similar embodied approaches give participants a way to track nervous-system state day to day, rather than only thinking about anxiety. We do not have trial data on when habit re-patterning is most accessible.
One-to-one integration is generally preferred over group-only for anxiety presentations, because anxiety often surfaces material that is harder to disclose in a group setting. A common failure mode in integration is “spiritual bypass” (Welwood), using insight and elevation to avoid the felt-sense work that anxiety actually requires.
See /safety/when-it-gets-hard for the screening-and-care framework that anxiety presentations move through during intake.
Practitioner perspective
“Fear during a ceremony often shows up as a body that is holding on. We slow the breath, ground in sensation, and let it move at its own pace.”
Considering psilocybin care for anxiety?
- Read our safety overview and medication guidance guides. Many anxiety medications require tapering or are absolute exclusions.
- If you are medically cleared, start with our intake conversation via /journeys/heal (free, 30 min, with a licensed facilitator). We will tell you honestly if Ceremonia is the right fit — or refer you elsewhere.
We do not accept self-bookings for clinical conditions.